仁度生物股票討論區

Despite a share price drop, Shanghai Rendu Biotechnology's P/S ratio is still high compared to industry peers, raising concerns due to its recent poor growth rate. If current medium-term revenue trends persist, it could significantly affect the share price, posing a risk to shareholders and potential investors.